Concentration–QTc analysis for single arm studies

[1]  Y. Kumagai,et al.  Novel concentration‐QTc models for early clinical studies with parallel placebo controls: A simulation study , 2020, Pharmaceutical statistics.

[2]  Y. Vugmeyster,et al.  Evaluation of the potential for QTc prolongation with avelumab , 2019, Cancer Chemotherapy and Pharmacology.

[3]  J. Pérez-Ruixo,et al.  Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors , 2019, Cancer Chemotherapy and Pharmacology.

[4]  F. Saad,et al.  An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer , 2018, Cancer Chemotherapy and Pharmacology.

[5]  Q. Dang,et al.  Evaluation of dependent variable, time effect, covariates, and covariation structure in concentration‐QTc modeling: A simulation study , 2018, Pharmaceutical statistics.

[6]  J. Infante,et al.  Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours , 2018, British journal of clinical pharmacology.

[7]  R. Sullivan,et al.  Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies , 2018, Cancer Chemotherapy and Pharmacology.

[8]  Michael J Crowther,et al.  Using simulation studies to evaluate statistical methods , 2017, Statistics in medicine.

[9]  Georg Ferber,et al.  Scientific white paper on concentration-QTc modeling , 2017, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  D. Mehrotra,et al.  Enabling robust assessment of QTc prolongation in early phase clinical trials , 2017, Pharmaceutical statistics.

[11]  K. Tabata,et al.  Population Pharmacokinetic-Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. , 2016, Clinical therapeutics.

[12]  Y. Wang,et al.  Operational Characteristics of Linear Concentration‐QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies , 2016, Clinical pharmacology and therapeutics.

[13]  B. Darpo,et al.  Detection of QTc Effects in Small Studies—Implications for Replacing the Thorough QT Study , 2015, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[14]  J. Moslehi,et al.  QT Prolongation and Oncology Drug Development. , 2015, Cardiac electrophysiology clinics.

[15]  David Hoffman.  Circadian Variation and Baseline Definition in Parallel-Group Thorough QT Studies , 2014, Therapeutic innovation & regulatory science.

[16]  G. Koch,et al.  Sample Size Calculations for Crossover Thorough QT Studies: Satisfaction of Regulatory Threshold and Assay Sensitivity , 2010, Journal of biopharmaceutical statistics.

[17]  Wendy R. Sanhai,et al.  Assessing proarrhythmic potential of drugs when optimal studies are infeasible. , 2009, American heart journal.

[18]  Alex Dmitrienko,et al.  Sample Size Calculations in Thorough QT Studies , 2008, Journal of biopharmaceutical statistics.

[19]  V. Piotrovsky,et al.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation , 2005, The AAPS Journal.